Study finds weight loss results drive continued Ozempic use despite nausea and other side effects, based on real world ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock earnings preview.

According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors. Although rare, semaglutide initiation can lead to ...

Indian pharmaceutical giant Dr Reddy’s Laboratories is gearing up to introduce a generic and significantly cheaper version of Novo Nordisk’s blockbuster weight-loss drug Wegovy. The company’s move ...

Joy Behar revealed on the Feb. 18 episode of The View that she lost 25 pounds using a GLP-1 drug—and she wasn't the only ...

GV Prasad, Co-Chairman & MD, Dr Reddy’s Lab said Canada could offer early market opportunity before competition increases. The company plans launches in multiple markets based on patent and approval ...

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Hims & Hers Health (NYSE:HIMS) launched a compounded semaglutide weight loss pill, then quickly discontinued it after a patent infringement lawsuit from Novo Nordisk. The company is under increased ...

Blockbuster weight-loss drugs are transforming the way we treat obesity. But while costly injectable versions remain out of ...

Semaglutide is indicated for the treatment of adults with inadequately controlled type 2 diabetes mellitus, as an adjunct to ...

By Tarun Sai Lomte Widely used weight-loss and diabetes drugs show clear benefits, but emerging evidence clarifies their side effects, rare risks, and what clinicians should monitor long term. Review: ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...